drugset / Trial / NCT00652782

Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure Patients

NCT00652782 ↗

Phase 2 Completed 160 enrolled Merck & Co., Inc. Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

A study to determine the most appropriate dose of MK7418 in heart failure patients presenting with symptoms of volume overload requiring increased diuretic doses.

Timeline

Start
2004-12
Primary completion
2005-08
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject rolofyline Unknown 2.5 mg Intravenous
Subject rolofyline Unknown 15 mg Intravenous
Subject rolofyline Unknown 30 mg Intravenous
Subject rolofyline Unknown 60 mg Intravenous